The levels of cyclin E1 and cyclin E2 were significantly elevated (23 vs 38%, respectively) in primary breast tumor samples relative to normal breast tissue controls.

Key Takeaways Zentalis Pharmaceuticals progresses with azenosertib in the DENALI trial for Cyclin E1-positive platinum-resistant ovarian cancer, aiming for FDA approval by 2026. Part 2a of the trial ...

About Cyclin E1 (CCNE1) MGDs Cyclin E1 (CCNE1) is a critical driver of cell cycle progression and cell proliferation that is frequently amplified or overexpressed in solid malignancies including ...

Two families of G1 cyclins operate in mammalian cells, D-type (D1, D2 and D3), which activate the cyclin-dependent kinases CDK4 and CDK6, and E-type (E1 and E2), which activate CDK2 (ref. 1).

Cyclin B is degraded by the ubiquitin pathway, a system involved in most selective protein degradation in eukaryotic cells. In this pathway, proteins are targeted for degradation by ligation to ...

Zentalis Pharmaceuticals Shares Updated Clinical Data Demonstrating Meaningful Azenosertib Activity in Cyclin E1+, Platinum-Resistant Ovarian Cancer Published Jan 29, 2025 7:00am EST ...

In the PALOMA-3 trial, 302 patients had tumor tissue analyzed (palbociclib arm, 194 patients; placebo arm, 108 patients). Palbociclib efficacy was lower in patients with high versus low cyclin E1 ...

FDA grants Fast Track Designation for azenosertib in Cyclin E1 positive cancer. Clinical data update to follow on January 29, 2025. Quiver AI Summary Zentalis Pharmaceuticals announced that the U ...

Cyclin-dependent kinases (CDK) are serine/threonine kinases that act as regulatory enzymes involved in cell proliferation. The dysregulation of CDK activity occurs through overexpression of cyclin E1, ...

Cedilla Therapeutics Inc. has synthesized cyclin-dependent kinase 2 (CDK2)/cyclin E1 inhibitors reported to be useful for the treatment of cancer, autoimmune diseases, Cushing syndrome, Alzheimer's ...

Our data have also confirmed Cyclin E1 overexpression as a predictor of sensitivity to azenosertib monotherapy in PROC, and we intend to pursue further development in this patient population.” ...

Results In the PALOMA-3 trial, 302 patients had tumor tissue analyzed (palbociclib arm, 194 patients; placebo arm, 108 patients). Palbociclib efficacy was lower in patients with high versus low cyclin ...